Fanconi Anemia Type C Gene Mutation Analysis
Fanconi Anemia Group C (FANCC) is an autosomal recessive genetic disease affecting 1:360,000 births with a carrier frequency of 1:300. It is found in some populations, including Ashkenazi Jewish, Spanish Gypsy, and black South African, with a carrier frequency of 1:100. There are 14 genes known to be involved in this disease, of which FANCC is one and is the most extensively studied. One of the genes, FANCD1, is caused by mutations in the BRCA2 gene. FANCC is characterized by bone marrow failure, physical abnormalities (e.g., short stature, malformation of digits, skeletal system, gastrointestinal system, eyes, ears, and heart defects), and an increased incidence of leukemia, anemia, and pancytopenia. Some patients are mentally retarded. As an autosomal recessive disease, an individual receiving two mutated copies of the FANCC gene will be affected.
FANCC is caused by mutations in the FANCC gene located on chromosome 9, specifically the 9q22.3 region. The FANCC gene encodes proteins in the Fanconi anemia pathway (FA) and is thought to work together with other genes associated with the FA pathway to regulate cellular resistance to DNA cross-linking agents. The FANCC gene is one of 14 genes that regulate DNA repair in the ubiquitin-phosphorylation network, dubbed the "FA pathway".
Clinical testing strategies for FANCC include: 1) confirmation testing to diagnose the disease, 2) presymptomatic, predictive testing of carrier status, and 3) prenatal testing to determine status of fetus with a family history of FANCC. Confirmation of disease status provides proper patient care and genetic information for at-risk relatives. Predictive testing determines genetic risk for individuals who have a family history of FANCC.
FANCC diagnosis is accomplished through cytogenetic and/or molecular genetic testing. FANCC is diagnosed via cytogenetic analysis of chromosome 9, measuring the chromosomal breakage or rearrangement in the presence of a bifunctional DNA interstrand cross-linking agent such as diepoxybutane (DEB) or the use of mitomycin C (MMC) for breakage analysis. Individuals with FANCC have increased rates of spontaneous chromosomal breakage and radial forms distinguishing FANCC from other types of chromosomal breakage syndromes.
FANCC diagnosis is also possible via molecular genetic testing of FANCC genes. The molecular basis of FANCC provides key factors for detection and predictive patient impacts. Molecular testing, such as targeted mutation analysis and DNA sequence analysis, is used to identify the presence of key mutations. The three most common mutations for FANCC genes in individuals of Ashkenazi Jewish ancestry are c.345+4A>T, p.Arg548X, and c.67del and three rare mutations are p.Gln13X, p.Arg185X, and p.Leu554Pro. Mutation c.345+4A>T has been found primarily in the Ashkenazi Jewish population with some reported in Japanese cohorts. The mutations p.Arg548X, c.67delG, p.Arg185X, and p.Leu554Pro are prevalent in individuals of northern European ancestry. The mutation p.Gln13X is found in individuals from southern Italy.
There is no cure for Fanconi anemia. The mainstays of treatment are androgens, hematopoietic growth factors, and allogeneic bone marrow transplantation. Transplantation cures the bone marrow disorder and reduces the risk of leukemia but does not lower risk for solid organ tumors or alter birth defects.
- Prenatal testing for at risk individuals
- Carrier testing for individuals of Ashkenazi Jewish ancestry
- Confirmation of clinical diagnosis
Positive: Deleterious.
Heterozygous mutation on 322delG and IVS4(+4)A>T FANCC gene might indicate carrier status. Homozygous mutation confirms disease.
Negative for mutation analyzed
Whole blood EDTA, or Whole Blood ACD.
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 days
1-2 weeks.
- Int J Hematol. 2011 Apr;93(4):417-24. [PMID: 21331524]
- J Med Genet. 2003; 40(1):1-10. [PMID: 12525534]
- Pediatrics. 1981;67(1):119-27 [PMID: 7243420]
- Hematology. 2005;10 Suppl 1:108-10. [PMID: 16188650]
- Fam Cancer. 2004;3:241-8. [PMID: 15516848]
- Nature. 1992;356:763-7. [PMID: 1574115]
- J Pediatr. 2004;145:125-7. [PMID: 15238921]
- Nat Genet. 1993;4:202-5. [PMID: 8348157]